Amgen second-quarter sales rise 9%, profit tops Street view

Amgen second-quarter sales rise 9%, profit tops Street view FILE PHOTO: The Amgen logo is seen in this illustration taken August 3, 2025. REUTERS/Dado Ruvic/Illustration/File Photo · Reuters By Deena Beasley Tue, August 4, 2026 at 10:06 PM GMT+2 3 min read AMGN By Deena Beasley Aug 3 (Reuters) - Amgen on Tuesday reported second-quarter sales rose 9%, driven by demand for cholesterol drug Repatha, bone drug Evenity and medications for rare diseases, as the company continues to develop ‌experimental weight-loss drug MariTide. The California-based biotech said it has discontinued development of a different obesity candidate known ‌as AMG 513, which was in early-stage clinical testing.

Amgen's second-quarter adjusted earnings rose 4% from a year earlier to $6. 29 per share, handily beating analysts' expectations ​of $5. 62, according to LSEG data.

The company's net earnings per share increased 65% to $4. 37. Quarterly revenue rose 10% from a year earlier to $10.

1 billion, surpassing the average Wall Street estimate of $9. 42 billion. Amgen raised its full-year outlook to adjusted earnings of $22.

30 to $23. 50 per share on revenue of $38. 2 billion to $39.

4 billion. It had previously projected 2026 earnings per share of $21. 70 to $23.

10 on revenue of $37. 1 billion to $38. 5 ‌billion.

"We delivered continued momentum across our six ⁠key growth drivers, which grew 26% year over year and represent nearly 70% of second-quarter product sales," CEO Robert Bradway said in a statement. The growth products he referred to are Repatha, ⁠Evenity for osteoporosis, asthma treatment Tezpire, rare disease drugs, novel oncology treatments and biosimilars. Quarterly sales of Repatha rose 37% to $953 million, beating analysts' expectations of $916 million.

Repatha, a PCSK9 drug given monthly or every two weeks by injection, is facing new competition from Merck's daily ​pill ​Lipfendra. "We are very pleased with the momentum now on Repatha," Murdo ​Gordon, Amgen's head of global markets and policy, ‌said in an interview. "The evidence that says that Repatha is effective in lowering the risk of first or second heart attacks is unrivaled.

" Sales of Evenity rose 38% to $714 million, ahead of analyst expectations of $645 million. Sales of older bone drug Prolia fell 32% to $759 million as patent expirations led to increased competition, but still beat analysts' estimates of $720 million. "Amgen is growing because we are serving more patients at lower unit prices," Gordon said.

"We would anticipate in the long range for ‌that trend to continue. " Sales of newer rare disease drug Uplizna increased 90% ​from a year ago to $335 million, while sales of Tavneos rose 36% ​to $150 million. The U.

S. Food and Drug Administration in ​April proposed the withdrawal of Tavneos, which is approved to treat a rare autoimmune disease, citing ‌a lack of proven effectiveness and concerns about ​integrity of trial data. Europe's drug ​regulator has also recommended revoking that drug's marketing authorization.

Story Continues Amgen said it is engaging with the FDA, has requested a hearing and submitted materials to the agency that it believes show Tavneos has a favorable benefit-risk profile. Initial ​results from Amgen's broad group of Phase ‌3 MariTide trials are not expected until next year. The drug, which is an injection given as ​infrequently as four times a year, is being tested for treating obesity and related conditions, including heart ​disease and sleep apnea.